Akero Therapeutics, Inc. Board of Directors

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Dr. Andrew Cheng M.D., Ph.D.

Dr. Andrew Cheng M.D., Ph.D.

President, CEO & Director

Mr. John J. Schembri

Mr. John J. Schembri

Senior VP & Head of Finance

Mr. William R. White J.D.

Mr. William R. White J.D.

Executive VP, CFO, Treasurer & Head of Corporate Development

Dr. Jonathan M. Young J.D., Ph.D.

Dr. Jonathan M. Young J.D., Ph.D.

Co-Founder, Executive VP, COO & Secretary

Ms. Catriona Yale

Ms. Catriona Yale

Executive VP & Chief Development Officer

Dr. Timothy Rolph Ph.D.

Dr. Timothy Rolph Ph.D.

Co-Founder & Chief Scientific Officer

Mr. Patrick Lamy

Mr. Patrick Lamy

Senior Vice President of Commercial Strategy

Mr. Scott A. Gangloff

Mr. Scott A. Gangloff

Chief Technical Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.